Novack David F 4

4 · DYNAVAX TECHNOLOGIES CORP · Filed Jan 20, 2026

Form 4

Period: 2026-01-15

President & COO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-15$6.80/sh+20,000$136,100→ 83,344 total
Exercise/Conversion
Common Stock
[F1]
2026-01-15$10.47/sh+94,000$984,180→ 177,344 total
Sale
Common Stock
[F1][F2]
2026-01-15$15.64/sh−114,000$1,782,960→ 63,344 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4][F3]
2026-01-15−20,000→ 146,528 total
Exercise: $6.80Exp: 2026-12-15→ Common Stock (20,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4][F3]
2026-01-15−85,655→ 0 total
Exercise: $10.47Exp: 2026-02-21→ Common Stock (85,655 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4][F3]
2026-01-15−8,345→ 0 total
Exercise: $10.47Exp: 2026-02-21→ Common Stock (8,345 underlying)

Footnotes (4)

[F1]The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 6, 2024.
[F2]This transaction was executed in multiple trades at prices ranging from $15.585 to $15.665; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
[F3]Fully vested.
[F4]Not applicable.

Signature

David F. Novack, by /s/ Trevor Dutcher, Attorney-in-Fact|2026-01-20

Documents

1 file